A Two-Part Clinical Study to Evaluate the Effect of Multiple Doses of MK-2828 on Rosuvastatin (Part 1) and Furosemide (Part 2) in Healthy Participants
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
Researchers are looking for other ways to treat people who have heart failure with preserved ejection fraction (HFpEF). HFpEF is a type of heart failure where the heart becomes stiff and does not relax properly. MK-2828 is a study medicine designed to treat HFpEF. The main goal of the study is to learn if MK-2828 affects what happens to rosuvastatin or furosemide in the body.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 24
Maximum Age: 60
Healthy Volunteers: t
View:
⁃ The main inclusion criteria include but are not limited to the following:
• Is in good health
• Has a body mass index (BMI) ≥18 and ≤32 kg/m\^2
Locations
United States
Florida
Fortrea Clinical Research Unit Inc ( Site 0001)
RECRUITING
Daytona Beach
Contact Information
Primary
Toll Free Number
Trialsites@msd.com
1-888-577-8839
Time Frame
Start Date: 2026-03-18
Estimated Completion Date: 2026-06-07
Participants
Target number of participants: 39
Treatments
Experimental: Rosuvastatin + MK-2828
Participants receive rosuvastatin and MK-2828 orally.
Experimental: Furosemide + MK-2828
Participants receive furosemide and MK-2828 orally.
Related Therapeutic Areas
Sponsors
Leads: Merck Sharp & Dohme LLC